Affimed N.V. (AFMDQ)
| Market Cap | 1.64K -100.0% |
| Revenue (ttm) | 6.29M -72.9% |
| Net Income | -78.04M |
| EPS | -5.07 |
| Shares Out | 16.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 105,476 |
| Average Volume | 5,690 |
| Open | 0.0001 |
| Previous Close | 0.0001 |
| Day's Range | 0.0001 - 0.0001 |
| 52-Week Range | n/a |
| Beta | 0.84 |
| RSI | 47.04 |
| Earnings Date | Jun 1, 2026 |
About Affimed
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatme... [Read more]
Financial Performance
In 2023, Affimed's revenue was 13.91 million, a decrease of -67.39% compared to the previous year's 42.67 million. Losses were -105.94 million, 23.2% more than in 2022.
Financial numbers in EUR Financial StatementsNews
Affimed Transcript: Leerink’s Global Healthcare Conference 2025
The session highlighted strong clinical progress for AFM24 and AFM28, with both programs showing promising efficacy and safety profiles in difficult-to-treat cancers. Strategic prioritization is ongoing, with investor and partner input guiding future development and financing decisions.
Affimed Transcript: Study Update
AFM24 plus atezolizumab showed robust efficacy and safety in heavily pretreated NSCLC, with higher drug exposure linked to improved outcomes. A new 720 mg cohort will open in 2025 to confirm enhanced response rates and PFS, supporting further clinical development.
Affimed Earnings Call Transcript: Q3 2024
Clinical programs for AFM24, AFM28, and acimtamig advanced, with key data updates at ASH 2024 and a December call for AFM24. Cash runway extends into Q4 2025, with reduced expenses and net loss. Strategic focus includes broadening partnerships and financial stability.
Affimed Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference
Three NK cell engager programs show strong efficacy and durability in refractory cancers, with AFM13 achieving high response rates in Hodgkin lymphoma and AFM24 demonstrating durable responses in NSCLC. Regulatory and commercial strategies are advancing, with pivotal data expected later this year.
Affimed Earnings Call Transcript: Q2 2024
Clinical programs in NSCLC, Hodgkin lymphoma, and AML showed strong early efficacy and safety, with financials reflecting reduced expenses and improved net loss. Cash runway extends into H2 2025, with key data readouts and strategic decisions expected in the next 12–24 months.
Affimed Earnings Call Transcript: Q1 2024
Clinical validation was achieved across all programs, with strong efficacy signals in difficult-to-treat cancers and improved financial efficiency. Durable responses were observed in lung cancer and lymphoma, and the company is well-positioned for further data readouts in 2024.
Affimed Transcript: Status Update
Combination of AFM24 and atezolizumab showed promising efficacy and manageable safety in heavily pretreated EGFR wild-type and mutant NSCLC patients, including those refractory to prior immunotherapy. Fast Track designation was granted, and further clinical development is planned.